Table 2.
Subject characteristics
| Placebo |
TOL ER |
|||||
|---|---|---|---|---|---|---|
| < 65 years (n = 1171) | 65–74 years (n = 477) | ≥ 75 years (n = 288) | < 65 years (n = 1360) | 65–74 years (n = 582) | ≥ 75 years (n = 285) | |
| Discontinuations, n (%) | ||||||
| Total* | 126 (11) | 49 (10) | 43 (15) | 115 (9) | 45 (8) | 35 (12) |
| Owing to an AE* | 37 (3) | 22 (5) | 16 (6) | 33 (2) | 14 (2) | 14 (5) |
| Men, n (%) | 265 (23) | 168 (35) | 118 (41) | 259 (19) | 180 (31) | 93 (33) |
| Mean (SD) age, years | 50.8 (9.9) | 69.0 (2.8) | 79.1 (4.0) | 50.7 (10.1) | 69.1 (2.8) | 78.9 (3.4) |
| Range | 19–64 | 65–74 | 75–93 | 18–64 | 65–74 | 75–90 |
| Race, n (%) | ||||||
| White | 1034 (88) | 452 (95) | 278 (97) | 1224 (90) | 555 (95) | 278 (98) |
| Black | 73 (6) | 15 (3) | 6 (2) | 71 (5) | 13 (2) | 4 (1) |
| Asian | 17 (2) | 4 (1) | 1 (< 1) | 18 (1) | 4 (1) | 2 (1) |
| Other | 47 (4) | 6 (1) | 3 (1) | 47 (3)† | 10 (2) | 1 (< 1) |
| Mean (SD) body mass index, kg/m2 | 29.1 (6.9) | 29.0 (5.9) | 26.6 (4.5) | 29.1 (9.0) | 28.9 (5.7) | 27.7 (12.4) |
| Range | 15.1–63.9 | 16.8–49.9 | 15.7–47.2 | 16.5–211.5 | 17.1–60.3 | 15.8–198.8 |
TOL ER, tolterodine extended release; AE, adverse event; *Discontinuations and AEs include those related to and those not related to the study drug; †Includes 1 subject who did not specify race.